1. Home
  2. ADAMI vs ANIP Comparison

ADAMI vs ANIP Comparison

Compare ADAMI & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADAMI
  • ANIP
  • Stock Information
  • Founded
  • ADAMI N/A
  • ANIP 2001
  • Country
  • ADAMI United States
  • ANIP United States
  • Employees
  • ADAMI N/A
  • ANIP N/A
  • Industry
  • ADAMI Real Estate Investment Trusts
  • ANIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • ADAMI Real Estate
  • ANIP Health Care
  • Exchange
  • ADAMI Nasdaq
  • ANIP Nasdaq
  • Market Cap
  • ADAMI 2.3B
  • ANIP 2.0B
  • IPO Year
  • ADAMI N/A
  • ANIP N/A
  • Fundamental
  • Price
  • ADAMI $25.22
  • ANIP $98.12
  • Analyst Decision
  • ADAMI
  • ANIP Strong Buy
  • Analyst Count
  • ADAMI 0
  • ANIP 9
  • Target Price
  • ADAMI N/A
  • ANIP $86.00
  • AVG Volume (30 Days)
  • ADAMI N/A
  • ANIP 488.4K
  • Earning Date
  • ADAMI N/A
  • ANIP 11-07-2025
  • Dividend Yield
  • ADAMI N/A
  • ANIP N/A
  • EPS Growth
  • ADAMI N/A
  • ANIP N/A
  • EPS
  • ADAMI N/A
  • ANIP N/A
  • Revenue
  • ADAMI N/A
  • ANIP $747,399,000.00
  • Revenue This Year
  • ADAMI N/A
  • ANIP $39.32
  • Revenue Next Year
  • ADAMI N/A
  • ANIP $9.62
  • P/E Ratio
  • ADAMI N/A
  • ANIP N/A
  • Revenue Growth
  • ADAMI N/A
  • ANIP 38.68
  • 52 Week Low
  • ADAMI N/A
  • ANIP $52.50
  • 52 Week High
  • ADAMI N/A
  • ANIP $99.50
  • Technical
  • Relative Strength Index (RSI)
  • ADAMI N/A
  • ANIP 77.55
  • Support Level
  • ADAMI N/A
  • ANIP $96.50
  • Resistance Level
  • ADAMI N/A
  • ANIP $99.50
  • Average True Range (ATR)
  • ADAMI 0.00
  • ANIP 2.17
  • MACD
  • ADAMI 0.00
  • ANIP -0.33
  • Stochastic Oscillator
  • ADAMI 0.00
  • ANIP 86.35

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Share on Social Networks: